Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1984 Jun 23;288(6434):1855–1857. doi: 10.1136/bmj.288.6434.1855

Systemic sclerosis: a collagen or microvascular disease?

M I Jayson
PMCID: PMC1441778  PMID: 6428575

Full text

PDF
1855

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Botstein G. R., Sherer G. K., Leroy E. C. Fibroblast selection in scleroderma. An alternative model of fibrosis. Arthritis Rheum. 1982 Feb;25(2):189–195. doi: 10.1002/art.1780250212. [DOI] [PubMed] [Google Scholar]
  2. Boucek R. J., Noble N. L. Histamine, norepinephrine, and bradykinin stimulation of fibroblast growth and modification of serotonin response. Proc Soc Exp Biol Med. 1973 Dec;144(3):929–933. doi: 10.3181/00379727-144-37714. [DOI] [PubMed] [Google Scholar]
  3. Boucek R. J., Speropoulos A. J., Noble N. L. Serotonin and ribonucleic acid and collagen metabolism of fibroblasts in vitro. Proc Soc Exp Biol Med. 1972 Jun;140(2):599–603. doi: 10.3181/00379727-140-36512. [DOI] [PubMed] [Google Scholar]
  4. Buckingham R. B., Prince R. K., Rodnan G. P., Taylor F. Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma). J Lab Clin Med. 1978 Jul;92(1):5–21. [PubMed] [Google Scholar]
  5. Campbell P. M., LeRoy E. C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975 May;4(4):351–368. doi: 10.1016/0049-0172(75)90017-7. [DOI] [PubMed] [Google Scholar]
  6. Castor C. W., Ritchie J. C., Williams C. H., Jr, Scott M. E., Whitney S. L., Myers S. L., Sloan T. B., Anderson B. E. Connective tissue activation. XIV. Composition and actions of a human platelet autacoid mediator. Arthritis Rheum. 1979 Mar;22(3):260–272. doi: 10.1002/art.1780220308. [DOI] [PubMed] [Google Scholar]
  7. FENNELL R. H., Jr, REDDY C. R., VAZQUEZ J. J. Progressive systemic sclerosis and malignant hypertension. Immunohistochemical study of renal lesions. Arch Pathol. 1961 Aug;72:209–215. [PubMed] [Google Scholar]
  8. Fries J. F., Lindgren J. A., Bull J. M. Scleroderma-like lesions and the carcinoid syndrome. Arch Intern Med. 1973 Apr;131(4):550–553. doi: 10.1001/archinte.1973.00320100078010. [DOI] [PubMed] [Google Scholar]
  9. Gay R. E., Buckingham R. B., Prince R. K., Gay S., Rodnan G. P., Miller E. J. Collagen types synthesized in dermal fibroblast cultures from patients with early progressive systemic sclerosis. Arthritis Rheum. 1980 Feb;23(2):190–196. doi: 10.1002/art.1780230209. [DOI] [PubMed] [Google Scholar]
  10. Goyle K. B., Dormandy J. A. Abnormal blood viscosity in Raynaud's phenomenon. Lancet. 1976 Jun 19;1(7973):1317–1318. doi: 10.1016/s0140-6736(76)92651-9. [DOI] [PubMed] [Google Scholar]
  11. Husson J. M., Druet P., Contet A., Fiessinger J. N., Camilleri J. P. Systemic sclerosis and cryoglobulinemia. Clin Immunol Immunopathol. 1976 Jul;6(1):77–82. doi: 10.1016/0090-1229(76)90062-3. [DOI] [PubMed] [Google Scholar]
  12. Jarrett P. E., Morland M., Browse N. L. Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J. 1978 Aug 19;2(6136):523–525. doi: 10.1136/bmj.2.6136.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Johnson R. L., Ziff M. Lymphokine stimulation of collagen accumulation. J Clin Invest. 1976 Jul;58(1):240–252. doi: 10.1172/JCI108455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kahaleh M. B., Leroy E. C. Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med. 1983 Apr;101(4):553–560. [PubMed] [Google Scholar]
  15. Kahaleh M. B., Osborn I., LeRoy E. C. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 1981 Apr;94(4 Pt 1):482–484. doi: 10.7326/0003-4819-94-4-482. [DOI] [PubMed] [Google Scholar]
  16. Kahaleh M. B., Osborn I., Leroy E. C. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med. 1982 May;96(5):610–613. doi: 10.7326/0003-4819-96-5-610. [DOI] [PubMed] [Google Scholar]
  17. Kahaleh M. B., Sherer G. K., LeRoy E. C. Endothelial injury in scleroderma. J Exp Med. 1979 Jun 1;149(6):1326–1335. doi: 10.1084/jem.149.6.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lapenas D., Rodnan G. P., Cavallo T. Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma). Am J Pathol. 1978 May;91(2):243–258. [PMC free article] [PubMed] [Google Scholar]
  19. LeRoy E. C. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest. 1974 Oct;54(4):880–889. doi: 10.1172/JCI107827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. MACDONALD R. A., ROBBINS S. L., MALLORY G. K. Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate. Proc Soc Exp Biol Med. 1958 Feb;97(2):334–337. doi: 10.3181/00379727-97-23734. [DOI] [PubMed] [Google Scholar]
  21. Mackel A. M., DeLustro F., Harper F. E., LeRoy E. C. Antibodies to collagen in scleroderma. Arthritis Rheum. 1982 May;25(5):522–531. doi: 10.1002/art.1780250505. [DOI] [PubMed] [Google Scholar]
  22. Maricq H. R., Spencer-Green G., LeRoy E. C. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med. 1976 Dec;61(6):862–870. doi: 10.1016/0002-9343(76)90410-1. [DOI] [PubMed] [Google Scholar]
  23. Maricq H. R. Wide-field capillary microscopy. Arthritis Rheum. 1981 Sep;24(9):1159–1165. doi: 10.1002/art.1780240907. [DOI] [PubMed] [Google Scholar]
  24. McGrath M. A., Peek R., Penny R. Blood hyperviscosity with reduced skin blood flow in scleroderma. Ann Rheum Dis. 1977 Dec;36(6):569–574. doi: 10.1136/ard.36.6.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Norton W. L., Nardo J. M. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med. 1970 Aug;73(2):317–324. doi: 10.7326/0003-4819-73-2-317. [DOI] [PubMed] [Google Scholar]
  26. ROSSI P., ZAMBONI L. Pulmonary arteriosclerosis due to serotonin. Nature. 1958 Apr 26;181(4617):1216–1217. doi: 10.1038/1811216a0. [DOI] [PubMed] [Google Scholar]
  27. Rosenbloom A. L., Silverstein J. H., Lezotte D. C., Richardson K., McCallum M. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med. 1981 Jul 23;305(4):191–194. doi: 10.1056/NEJM198107233050403. [DOI] [PubMed] [Google Scholar]
  28. Seibold J. R. Digital sclerosis in children with insulin-dependent diabetes mellitus. Arthritis Rheum. 1982 Nov;25(11):1357–1361. doi: 10.1002/art.1780251112. [DOI] [PubMed] [Google Scholar]
  29. Seibold J. R., Medsger T. A., Jr, Winkelstein A., Kelly R. H., Rodnan G. P. Immune complexes in progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1982 Oct;25(10):1167–1173. doi: 10.1002/art.1780251004. [DOI] [PubMed] [Google Scholar]
  30. Siminovitch K., Klein M., Pruzanski W., Wilkinson S., Lee P., Yoon S. J., Keystone E. Circulating immune complexes in patients with progressive systemic sclerosis. Arthritis Rheum. 1982 Oct;25(10):1174–1179. doi: 10.1002/art.1780251005. [DOI] [PubMed] [Google Scholar]
  31. Stachow A., Jablonska S., Skiendzielewska A. 5-Hydroxytryptamine and tryptamine pathways in scleroderma. Br J Dermatol. 1977 Aug;97(2):147–154. doi: 10.1111/j.1365-2133.1977.tb15060.x. [DOI] [PubMed] [Google Scholar]
  32. Stachów A., Jabłońska S., Skiendzielewska A. Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma. Acta Derm Venereol. 1979;59(1):1–5. [PubMed] [Google Scholar]
  33. Tan E. M., Pearson C. M. Rheumatic disease sera reactive with capillaries in the mouse kidney. Arthritis Rheum. 1972 Jan-Feb;15(1):23–28. doi: 10.1002/art.1780150104. [DOI] [PubMed] [Google Scholar]
  34. Tan E. M., Rodnan G. P., Garcia I., Moroi Y., Fritzler M. J., Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980 Jun;23(6):617–625. doi: 10.1002/art.1780230602. [DOI] [PubMed] [Google Scholar]
  35. Wasner C., Cooke C. R., Fries J. F. Successful medical treatment of scleroderma renal crisis. N Engl J Med. 1978 Oct 19;299(16):873–875. doi: 10.1056/NEJM197810192991607. [DOI] [PubMed] [Google Scholar]
  36. Whitman H. H., 3rd, Case D. B., Laragh J. H., Christian C. L., Botstein G., Maricq H., Leroy E. C. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum. 1982 Mar;25(3):241–248. doi: 10.1002/art.1780250301. [DOI] [PubMed] [Google Scholar]
  37. Winkelmann R. K., Goldyne M. E., Linscheid R. L. Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol. 1976 Jul;95(1):51–56. doi: 10.1111/j.1365-2133.1976.tb15534.x. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES